- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03967990
Corn and Heart Health Study (CHS)
Evaluating the Effects of Corn Flour Consumption on Cardio-metabolic Outcomes and the Gut Microbiome in Adults With High Cholesterol
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Dietary fibers are extremely complex and foster health in a variety of ways that are not fully understood. The Adequate Intake of fiber (14 g per 1000 kcal consumed) is based on data that strongly support a relationship with cardiovascular disease prevention (Slavin, 2013). While cereal fibers have been shown to be most effective at reducing cardiovascular disease risk (IOM, 2002), the components of dietary fiber (e.g. germ, bran) that exert this effect remain inadequately studied in cardiometabolic outcomes. Further, specific types of dietary fiber (natural and synthetic) have been shown to increase beneficial microbial species in the gastrointestinal tract, which are accompanied by improvements in inflammatory and metabolic disease markers. Very little is known about how isolated or intact fiber in whole grains solicit beneficial health effects via microbial mechanisms. Our goal is to study both changes in cardiometabolic outcomes and the gut microbiome after consuming different types of corn-based meals.
Aim 1: To evaluate cardio-metabolic outcomes (primary outcome: LDL cholesterol) after consuming 48 g/d of whole grain corn flour, 50% refined corn flour + 50% corn bran derived from whole corn meal, and refined corn flour for 4 weeks in adult males and females with elevated LDL cholesterol in a crossover design.
Aim 2: To evaluate changes in the gut microbiome after consuming 48 g/d of whole grain corn flour, 50% refined corn flour + 50% corn bran derived from whole corn meal, and refined corn flour for 4 weeks in adult males and females with elevated LDL cholesterol in a crossover design.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Corrie M Whisner, PhD
- Phone Number: 602-496-3348
- Email: cwhisner@asu.edu
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85007
- Arizona Biomedical Collaborative
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy English and Spanish speaking males and females with elevated circulating cholesterol levels (LDL-c ≥ 120 mg/dL).
- Individuals with LDL-c > 190 mg/dL will be permitted to participate but must provide a letter from their doctor stating that they are comfortable with their participation in the study.
Exclusion Criteria:
- recent weight fluctuations (> 5 lb in past 3 months), following specialized or restrictive diets (e.g. carbohydrate restriction, veganism)
- use of supplements (antioxidants, fiber, botanicals)
- allergies to dairy, egg, wheat, corn or gluten
- use of antibiotics in the past 2-3 months
- use of lipid lowering medications
- regular physical activity ≥ 30 min/d for ≥ 5 days/wk
- history of thyroid disorders, diabetes, heart disease, cancer, hepatitis, inflammatory conditions and/or gastrointestinal disorders which may impact gut function and metabolism
- anyone with a fear of needles or blood draws
- If female, women may not be pregnant or lactating during the study.
- Unwillingness to comply with study protocols will also result in exclusion from the study.
- Participants in this study will not be eligible if they are participating in other research studies at the same time.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: refined-50/50-whole
48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) whole grain cornmeal flour
|
48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
|
Experimental: 50/50-whole-refined
48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) whole grain cornmeal flour, followed by (3) refined cornmeal flour
|
48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
|
Experimental: whole-refined-50/50
48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) refined cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
|
48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
|
Experimental: refined-whole-50/50
48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) refined cornmeal flour, followed by (2) whole grain cornmeal flour, followed by (3) 50/50 mix of refined cornmeal flour plus corn bran
|
48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
|
Experimental: 50/50-refined-whole
48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) 50/50 mix of refined cornmeal flour plus corn bran, followed by (2) refined cornmeal flour, followed by (3) whole grain cornmeal flour
|
48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
|
Experimental: whole-50/50-refined
48 g/d of corn flour was delivered to participants in two daily 24 g servings as pita breads and/or muffins via (1) whole grain cornmeal flour, followed by (2) 50/50 mix of refined cornmeal flour plus corn bran, followed by (3) refined cornmeal flour
|
48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL Cholesterol
Time Frame: 0 weeks, 4 weeks
|
Serum LDL cholesterol concentrations will be measured at the 0 and 4 weeks for each cornmeal intervention
|
0 weeks, 4 weeks
|
HDL Cholesterol
Time Frame: 0 weeks, 4 weeks
|
Serum HDL cholesterol concentrations will be measured at the 0 and 4 weeks for each cornmeal intervention
|
0 weeks, 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gut Microbiome Diversity
Time Frame: 0 weeks, 4 weeks
|
Fecal gut microbiome communities will be sequenced using microbial DNA extracted from samples at 0 and 4 weeks for each cornmeal intervention.
Amplified copies of the 16S rRNA gene will be evaluated for treatment differences in alpha (within-sample richness and evenness) and beta diversity (between-sample community structure).
Relative and differential abundance of individual microbial taxa will also be measured.
|
0 weeks, 4 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Corrie M Whisner, PhD, Arizona State University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- STUDY00007518
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gut Microbiome
-
University of California, DavisCompletedGut Microbiome | Skin Microbiome | Gut Lipidome | Skin Lipidome | Blood LipidomeUnited States
-
ProgenaBiomeRecruitingGastrointestinal Microbiome | Gut MicrobiomeUnited States
-
University College CorkAIT Austrian Institute of Technology GmbHNot yet recruiting
-
Evolve BioSystems, Inc.University of California, DavisCompletedGut MicrobiomeUnited States
-
State University of New York at BuffaloCompleted
-
Access Business GroupCompletedGut MicrobiomeUnited States
-
Washington University School of MedicineCompleted
-
Evolve BioSystems, Inc.Terminated
-
Evolve BioSystems, Inc.CompletedInfant Gut MicrobiomeUnited States
Clinical Trials on Refined cornmeal flour
-
Purdue UniversityCompletedObesity | Diabetes Mellitus, Type 2 | Appetitive BehaviorUnited States
-
Tufts UniversityAgriculture and Agri-Food CanadaCompleted
-
Universidade Federal do Rio de JaneiroCompletedDietary ModificationBrazil
-
Peking UniversityCompleted
-
Massachusetts General HospitalNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of CopenhagenBARILLA G. e R. Fratelli S.p.A., Parma, Italy; the European Commission in the...Completed
-
South Dakota State UniversityCompleted
-
University of ManitobaSaskatchewan Pulse Growers; Alberta Pulse GrowersCompleted
-
University of MinnesotaCompleted